comprehensive -WSS

comprehensive

author：leisure time 2025-09-29 21:24:09 - browse：3192

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： International team creates first chimeric human

leisure time

entertainment

WSS

FogPharma raises $145 million in rare Series E round

Scientists unlock the key to scar

Biotech companies concerned about China biosecurity crackdown

Guardant Health colon cancer test endorsed by FDA advisory panel

Scientists unlock the key to scar

Stroke rates rising, especially in working

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Tori Bowie and the unacceptable rates of Black maternal death

Protect nursing home residents from future pandemics

Bright Health sells Medicare Advantage business to Molina

Some medical students still think black patients feel less pain

Novavax promises a turnaround & Lilly roils the obesity market

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

As demand for Covid shots wanes, Moderna seeks its next success

Change Healthcare cyberattack outage could last weeks

Wildfire smoke exposes gaps in outdoor worker protections

A Q&A with Aletha Maybank, AMA’s chief health equity officer

leisure time

Flu vaccine offering decent levels of protection this winter, new data show

Should insurance cover cosmetic surgery?

Hospitals need to get ahead of regulations on climate change

House looks to weaken Medicare negotiation

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Achieving telehealth equity for people with hearing loss

leisure time

entertainment

entertainment

hotspot